Home › Conditions › Superior Vena Cava Obstruction (SVCO)
Oncology
Superior Vena Cava Obstruction (SVCO)
Superior vena cava obstruction (SVCO) causes progressive facial oedema, arm oedema, JVD, and dyspnoea, with a positive Pemberton's sign (facial flushing/cyanosis on arm elevation). The commonest malignant cause is SCLC, followed by lymphoma and central line thrombus. CT chest with IV contrast confirms diagnosis and identifies the underlying cause to guide treatment.
UKONS / NICE SVCO Guidance
The pathway
Recognise and assess severity
- Facial oedema (worse lying flat or bending forward)
- Arm oedema and JVD
- Pemberton's sign: ask patient to raise both arms — positive if face flushes or becomes cyanotic
- Stridor or reduced GCS → emergency intervention
- Assess dyspnoea severity and SpO₂
Imaging and tissue diagnosis
- CT chest with IV contrast: confirms SVC obstruction, extent, and identifies primary cause
- CXR may show mediastinal widening or right hilar mass
- Obtain tissue biopsy if cause unknown — CT-guided percutaneous or bronchoscopy
- Do not delay stenting for biopsy in emergency presentations
Dexamethasone
- Dexamethasone 8mg BD PO or IV
- Reduces peri-tumoural oedema — symptom improvement within 24–48 hours
- Start immediately on clinical diagnosis
- Add omeprazole 20mg OD for gastric protection
SVC stenting for urgent/emergency cases
- Endovascular SVC stenting is the fastest way to relieve obstruction (relief within 24–72h)
- Indicated for severe or rapidly progressive symptoms, stridor, or haemodynamic compromise
- Interventional radiology via femoral or subclavian approach
- Effective regardless of histology — does not preclude subsequent chemotherapy or radiotherapy
Chemotherapy for chemo-sensitive tumours
- SCLC: platinum-based chemotherapy — high response rate; may be first-line if tissue confirmed
- Lymphoma: R-CHOP or equivalent — chemotherapy is first-line
- Liaise with oncology team — do not delay stenting for chemotherapy in emergency
Radiotherapy
- NSCLC or tumours not amenable to chemotherapy: palliative radiotherapy to mediastinum
- Emergency radiotherapy if stenting unavailable
- Slower onset than stenting — response over days to weeks
Anticoagulation for thrombotic cause
- Central line thrombus: therapeutic LMWH (enoxaparin 1.5mg/kg OD SC)
- Consider central line removal if thrombus is line-related and alternative access available
- Tumour-related: anticoagulation adjunct to stent/oncological treatment
Drugs
| Drug | Dose | Route | Notes |
|---|---|---|---|
| Dexamethasone | 8mg BD | PO or IV | Start immediately. Reduces peri-tumoural oedema. Add omeprazole cover. Taper once definitive treatment initiated. |
| Omeprazole | 20mg OD | PO | Gastric protection during dexamethasone course. |
| Enoxaparin | 1.5mg/kg OD | SC | Thrombotic SVCO or central line thrombus. Preferred over DOAC in active malignancy. |
| Furosemide | 40mg | PO or IV | For symptomatic oedema if volume overloaded. Use cautiously — venous return is obstructed in SVCO. |
When to escalate
- Stridor or airway compromise — emergency SVC stenting or radiotherapy; anaesthetics for airway assessment
- Reduced GCS or haemodynamic compromise — ICU, emergency stenting
- Unknown primary — urgent tissue biopsy before chemotherapy unless life-threatening urgency
- SCLC or lymphoma confirmed — urgent oncology referral for chemotherapy alongside stenting
- Central line thrombus causing SVCO — haematology referral, consider line removal and therapeutic anticoagulation
Reference: UKONS / NICE Oncological Emergencies Guidance / ESMO SVCO Clinical Practice Guidelines 2021
Practise and explore
Practise a case or explore differentials here on the website. The optional browser app adds personal learning tools and saved progress.